Cyclopharm Limited announced it has appointed Dr. Michael Guo to the role of Clinical Program Director. In that role, Dr. Guo will be responsible for supervising Cyclopharm's clinical trial programme, a key element of the company's growth strategy, including expanding clinical indications and applications for Technegas to include disease states such as Chronic Obstructive Pulmonary Disease (COPD), Asthma, Lung Cancer and Pulmonary Hypertension. Dr. Guo will also provide major support for the company's efforts to enter new and emerging markets including the People's Republic of China and the United States. Most recently Dr. Guo served as the Clinical Research Scientist and Network Coordinator for Austral-Asian Severe Asthma Network at the Woolcock Institute of Medical Research.